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1. Introduction 
Coronary artery bypass grafting (CABG) is one of the most studied operations in medical 
history, but many of the data forming the basis for clinical decisions in patients with 
coronary artery disease (CAD) were derived in the 1970s and 1980s, when the procedure 
and medical therapy were in their relative infancy. Advances in medical therapy (beta 
adrenergic blockers, thienopyridines, statins, and others), percutaneous coronary 
interventions (PCI), and surgical techniques have changed the decision making for patients 
with CAD. In addition, patient populations referred for surgery have changed since the 
original studies documenting advantages of CABG over other forms of therapy. 
Since percutaneous transluminal coronary angioplasty (PTCA) was introduced, significant 
advances have been made in the percutaneous treatment of CAD. When drug-eluting stents 
(DES) were introduced in the early 2000s, many predicted the demise of CABG surgery. 
Enthusiasm for percutaneous treatment of CAD has most recently led to promoting PCI for 
unprotected left main coronary artery (LMCA) disease, an anatomical state typically 
reserved for CABG [1-3]. Percutaneous options have indelibly changed the face of CABG 
surgery and raise questions concerning the “gold standard” of care in coronary 
revascularization. For instance, recent reports document that patients referred for redo 
coronary artery surgery have declined, presumably due to the increased enthusiasm, 
possibly among surgeons themselves, for PCI in this setting [4]. Despite this, few studies 
have actually compared PCI with CABG. Two notable studies are recently available, both 
demonstrating advantages for CABG over PCI for left main CAD and/or three-vessel CAD 
[5, 6].  
Concurrently, details pertaining to short-term outcomes of CABG have been questioned. For 
example, historical saphenous vein graft (SVG) patencies were reported as approximately 
50% at 10 years [7]. However, several studies published in the mid-2000s indicate that early-
term patencies of aorto-coronary SVG conduits are not as good as the historical figures that 
are still often quoted [8-10]. While the long-term patency and performance of the left 
internal mammary artery (LIMA) has not been questioned, the recent poor performance of 
                                                                 
* Corresponding Author 
www.intechopen.com
 
Special Topics in Cardiac Surgery 144 
SVG, coupled with increasing enthusiasm and demand for DES has lead to the emergence of 
“hybrid” coronary revascularization, typically consisting of LIMA-to-LAD and PCI of other 
coronary lesions. [11].  
Coronary artery surgery itself has undergone several iterative changes recently. In the 1990s, 
great enthusiasm existed for the “mid-CAB” (minimally-invasive direct coronary artery 
bypass) procedure, an approach integral to “hybrid” revascularizations and primarily 
involving a small left anterior thoracotomy to harvest the LIMA and expose the left anterior 
descending [LAD] coronary artery. However, outside of the context of hybrid procedures, 
mid-CAB has had little widespread applicability, particularly since most patients referred 
for coronary surgery have multivessel disease. Introduction of mid-CAB procedures help 
usher in the era of off-pump CABG, which was heralded as an approach to reduce the risks 
associated with on-pump CABG, particularly myocardial dysfunction and cerebrovascular 
complications [12]. Finally, technology has introduced minimally invasive platforms for 
performing multi-vessel CABG, most recently the introduction of “totally endoscopic” and 
robotic CABG surgery [13]. However, it should be noted that these “improved techniques” 
continue to utilize the same conduit selection and comparative trials with objective evidence 
are lacking. Since minimally invasive strategies for CABG do not routinely incorporate 
changes to the operation known to improve short- and long-term results, there appears little 
reason to suspect that graft patency rates will be improved by less invasive procedures. 
Rather, one could argue that these alterations in approach to CABG are primarily based on 
industry involvement, public demands for less invasive procedures, and as marketing 
strategies by hospital systems. 
Are there alternatives to CABG, which could improve long-term outcomes for graft patency and the 
composite of major adverse coronary events (MACE) particularly when compared with PCI? The 
answer is a resounding “yes,” and it is found in arterial conduits for coronary bypass. CABG 
with multiple arterial grafts have been shown to have improved graft patency, reduced need 
for reoperation or reintervention, and prolonged survival compared with patients 
undergoing CABG with one IMA and SVG [14-17]. For instance, Sabik et al reviewed a 27-
year experience at the Cleveland Clinic with regard to need for reintervention after primary 
CABG and found that the extent of arterial grafting correlated with freedom from 
subsequent reintervention [18]. Specifically, patients who received two IMA grafts at initial 
surgery had approximately 10% risk for reintervention at 10 years; those with one IMA had 
20% risk; and those with no IMA had approximately 30% risk for reintervention at 10 years 
[18].  
However, the surgical community has not fully utilized these assets despite numerous, 
compelling data [19-23]. Jones succinctly summarized the decision point facing 
conventional, open surgery in the face of rapidly advancing technologies, particularly PCI, 
and the impact on referral trends for surgical intervention: “ improve the long-term 
outcome, lessen resources used, or both.” [24]. Therefore, one important philosophic 
principle regarding use of multiple arterial conduits is that the focus is on the long-term 
results, not the short-term.  
The purpose of this chapter is to review the data available for CABG with multiple arterial 
grafts including bilateral IMA use, radial artery, and other conduits. Finally, we will 
demonstrate the advantages of multiple arterial grafting and make the argument that this 
strategy yields superior long-term results compared to any strategy for coronary 
revascularization based on PCI or CABG with traditional conduit selection.  
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2. Percutaneous coronary interventions 
PCI was introduced in 1977 and has undergone consistent improvements in technologies 
and approaches, offering a less invasive treatment modality for CAD [25]. With the 
introduction of DES in 2003, the percentage of CAD patients treated with PCI have 
increased consistently [26, 27]. However, recent studies evaluating long-term outcomes for 
DES have revealed increased morbidity and mortality secondary to late stent thrombosis 
[28-30]. While DES therapy has reduced need for target lesion reintervention [31, 32], there is 
a strict therapeutic requirement for dual anti-platelet therapy (DAPT). Current DAPT 
recommendations are for at least one year after DES therapy, but the ideal length of 
treatment still not yet known [33]. 
3. Comparing coronary bypass surgery and PCI 
Shortly after the emergence of PCI as a reliable and durable therapy for CAD, comparisons 
between angioplasty and CABG were designed in order to determine the relative 
advantages of each modality. The BARI (Bypass Angioplasty Revascularization 
Investigation) trial compared balloon angioplasty with CABG in patients with multivessel 
CAD and severe angina or inducible coronary ischemia. After 5 and 10 years follow-up, no 
difference in long-term survival was demonstrated [34, 35]. Similar results were noted in 
other randomized trials of PTCA versus CABG [36, 37]. It was commonly noted in these 
trials that reintervention for recurrent angina symptoms was significantly more common for 
patients treated with an initial strategy of PTCA [BARI, RITA, GABI]. However, on 
subgroup analysis, survival advantage for CABG was demonstrated among diabetic 
patients in the BARI trial [35]. Finally, a meta-analysis of 13 randomized controlled trials 
comparing CABG with PTCA showed improved survival for CABG at 5-8 years in those 
with multivessel CAD and in diabetic patients [38].  
Even as studies comparing PTCA with CABG were enrolling, bare-metal stents (BMS) were 
introduced, and trials to compare the new technology with CABG emerged. The 
randomized Stent or Surgery (SoS) trial compared multivessel CAD treatment by CABG or 
by PCI with BMS [39]. At a median follow-up of 2 years, these data showed reduced rates of 
coronary reintervention and significantly fewer deaths after CABG. Similar trials comparing 
CABG and PCI with BMS did not demonstrate a survival advantage for either therapy [40], 
although diabetic patients appeared to have improved survival after CABG in the Arterial 
Revascularization Therapies Study (ARTS 1) [41].  
The US Food and Drug Administration approved DES therapy in 2003, stimulating another 
round of comparisons between CABG and PCI with the newer technology. Hannan et al 
reviewed risk-adjusted data from the NY State Dept of Health comparing patients who 
underwent CABG or PCI with DES for multivessel CAD over a 15-month period shortly 
after DES approval [5]. At a mean follow-up of 19 months, CABG patients experienced 
reduced hazard ratio for death, reduced mortality, reduced death/myocardial infarction 
composite, and less need for repeat revascularization [5]. However, the data were not 
acquired in the context of a randomized trial. Finally, the SYNTAX trial, a prospective 
randomized trial conducted across Europe and the US, compared PCI with DES and CABG 
in patients with 3-vessel CAD, left main CAD, or both [6]. The primary outcomes were 
major adverse cardiovascular or cerebrovascular events, and follow-up was provided for 12 
months after intervention. The SYNTAX data demonstrated increased rates of MACE in the 
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PCI group, primarily related to the increased need for repeat intervention. Death and post-
procedure MI were not significantly different between the two groups, but there was an 
increased stroke rate in the CABG group compared with PCI, which is somewhat offset by 
the fact that surgical patients were not managed with aggressive antiplatelet therapy as 
compared to the PCI group, and many of the cerebrovascular events occurred outside of the 
perioperative period. More recently, three-year follow up SYNTAX data were reported 
confirming advantages of CABG over PCI with regard to MACE. Unlike 12-month data, 
however, composite safety endpoints were no longer different between the two groups, 
including a similar stroke rate [42]. The SYNTAX authors concluded that CABG remains the 
preferred therapy for 3-vessel or left main CAD but recommend longer follow up, as is 
planned for an additional two years [6].  
Despite the favorable data for CABG emanating from carefully designed and conducted 
randomized trials, rates of CABG referral have decreased consistently since the introduction 
of PCI with stent technologies [43]. Preference for PCI appears driven by disparate 
interpretation of PCI-versus-CABG studies, by strong patient preference for less invasive 
procedures with presumed lower periprocedural risk, and by the promise for faster 
recovery. As a result, the percentage of patients referred for CABG with previous PCI has 
increased steadily [44] with higher acuity relative to patients without previous intervention 
[45]. Additionally, technical details of CABG in current surgical practices are considered 
more challenging compared with previous eras due to more diffuse CAD, subjectively 
smaller distal coronary targets, particularly among diabetic patients, and the high incidence 
of prior PCI [46]. Consequently, contemporary results for CABG following PCI are 
characterized by worse perioperative outcomes when compared with CABG patients 
without previous intervention. For example, higher rates of postoperative mortality, MACE, 
and other perioperative complications following CABG in both diabetic and nondiabetic 
patients have been observed [47-50]. More importantly, increased mid-term mortality in 
diabetic patients with prior PCI has been observed after CABG [50], and Rao et al 
demonstrated increased long-term mortality in patients with prior PCI who subsequently 
underwent CABG [51]. 
4. Saphenous vein graft conduits 
Reversed saphenous vein grafts (RSVG) have been utilized for CABG since the procedure’s 
inception [52] and remain an important graft conduit option in the present era and in 
numerous clinical scenarios [53, 54]. Historically, patency rates of RSVG aorto-coronary 
artery grafts have been observed to be approximately 50-60% at 10 years [7, 55]. However, as 
previously noted, recent RSVG patency data are less encouraging [8-10]. For example, the 
PREVENT-IV study evaluated 3,000 patients undergoing CABG with 1-year routine 
angiographic follow-up. At this early time point, 30% of RSVG conduits were occluded and 
over 45% had “failed,” as defined by  75% stenosis [10]. Importantly, study patients with 
vein graft failure had significantly increased rates of perioperative complications including 
MI, death or MI, or MACE relative to the cohort without vein graft complications [10]. 
Similar results have been noted elsewhere [56-59]. Additionally, surprisingly poor early-to-
mid-term RSVG patency rates have been reported elsewhere. The Portland Endoscopic SVG 
Harvest Trial demonstrated 69% [8], patency by angiography at 6-months, while the 
PRAGUE 4 trial showed one-year RSVG patency of 52.5% [9]. The potential impact of poor 
vein graft performance cannot be overstated as RSVG failure is significant contributor to 
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redo coronary surgery [60]. In addition, early vein graft failure is associated with increased 
perioperative myocardial infarction [10, 61], which consequently affects survival after CABG 
[58, 59]. 
Several potential explanations exist for the recently chronicled poor performance of RSVG as 
aorto-coronary conduits including early technical errors, endothelial injury, and early 
thrombosis, which may be related to insufficient biologic reaction to aspirin or inadequate 
antiplatelet effect of aspirin [62-64]. One important contributor to poor RSVG conduit 
performance, receiving significant recent attention, may be the practice of harvesting the 
conduit endoscopically (EVH). This technique was introduced and popularized in the 1990s 
and has been widely adopted due to increased incisional comfort and patient satisfaction, 
and decreased wound complications compared to open vein harvesting [65, 66] such that at 
least 70% of CABG patients undergo EVH based on recent Society of Thoracic Surgeons 
Database reporting [67]. However, EVH has been associated with increased endothelial 
injury, which may have significant negative consequences including graft patency and 
possibly long-term survival [68, 69]. Desai et al recently demonstrated using optical 
coherence tomography that EVH operators had a steep learning curve with regard to subtle 
RSVG injuries and that vein grafts with four or more intimal or medial dissections showed 
significantly worse early patency rates than those with fewer intimal injuries (67% vs. 96%) 
[70].  
In contrast, when RSVGs are harvested using a “no touch” technique, better patency results 
have been noted. The “no touch” method avoids vein stripping, taking surrounding tissue, 
and avoids over-distending the vein conduit as it is being prepared for coronary 
anastomosis [71]. This has also been shown recently to preserve the venous vasa vasorum 
[72]. Perhaps this helps to explain differences in contemporary SVG patency rates versus 
those reported historically, which were always done by an open surgical technique. Other 
predictors of improved vein patency include grafting to the LAD coronary artery versus 
other target sites, smaller venous conduit size, and larger diameter target coronary artery. In 
contrast, young age and low EF reduced long-term patency [60]. The type of distal 
anastomosis (sequential, y- or t-grafts, or other composite grafts) did not affect long-term 
patency [60]. Based on these data, some suggest SVG from the calf/lower leg since size and 
possible thickness of the vein is better [60]. Additionally, EVH is more difficult to perform 
on the lower leg; therefore, programs committed to EVH likely neglect this potentially 
advantageous conduit.  
Current surgical patient cohorts have also been implicated in reduced vein graft patencies. 
For example, it is generally accepted that contemporary patients referred for surgery are 
older and more medically complex [73]. For example, many patients referred for CABG are 
diabetic, a condition that is notorious for more complicated and diffuse CAD [46, 74]. In 
addition, it has been proposed that venous grafts in elderly may be of inferior quality 
relative to younger patients [75]. 
5. General advantages of arterial grafting 
Several advantages to arterial grafting have been demonstrated relative to CABG without 
arterial grafts. Most notably, the LIMA-LAD graft has been shown to be an independent 
predictor of survival after CABG when compared with patients not receiving LIMA-LAD 
[76]. In addition, using more than one IMA graft reduces the need for subsequent 
reintervention and prolongs survival relative to patients receiving only one arterial grafts 
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[15, 17]. Similarly, Guru et al evaluated the potential benefit of multiple arterial grafting in 
over 53,000 patients undergoing primary CABG between 1991 and 2001. After propensity 
matching, patients receiving  2 arterial grafts had decreased rates of cardiac readmission 
and reduced incidence of the composite of cardiac readmission, death, and repeat 
revascularization relative to those with  one arterial grafts [23]. Furthermore, patients 
receiving  2 arterial grafts had improved survival compared with patients receiving only 
one arterial graft [23]. Similar findings were reported by Nasso, et al, who found no 
differences at 2 years between groups receiving RA, in-situ RIMA, or free RIMA as the 2nd 
arterial graft, although each of these groups was superior to patients receiving only one 
arterial graft (LIMA-LAD) with respect to cardiac event-free survival [77]. Zacharias et al 
also demonstrated advantages of RA grafting as a 2nd arterial conduit on long-term survival 
when compared to RSVG conduits [14]. 
In addition, multiple arterial grafts and their arrangements in all coronary distributions 
have been proven superior to venous grafts with regard to long term patency regardless of 
the anatomic details of the native coronary and distal anastomosis [55]. These results are 
particularly applicable in the context of recurrent angina [16, 55, 78]. Finally, perhaps one of 
the best recent demonstrations of the advantages of arterial grafting over RSVG conduits 
was provided by Gaudino et al, who studied 60 CAD patients who had previously 
undergone PCI and developed in-stent restenosis. After undergoing CABG, patients 
receiving IMA and RA grafts had patency rates of 90% while those undergoing RSVG had 
patency rates of 50% at a mean follow-up of 52 months [79]. 
5.1 Total arterial revascularization 
Since SVG conduits inevitably fail, particularly late [62], there has been increased 
enthusiasm for total arterial revascularization for CABG. Total arterial revascularization 
may obviate the concerns of vein graft failure and has been shown to have good short-
term results [80]. However, little evidence is available to suggest that outcomes are 
improved with “all-arterial” grafting [81]. Zacharias et al have recently demonstrated that 
patients with multi-vessel CAD undergoing all-arterial grafting had improved 12-year 
survival compared with matched patients who underwent standard CABG with LIMA-
LAD and RSVG to other distal targets [82]. Furthermore, complete coronary 
revascularization and use of all-arterial grafting strategy was associated with improved 
12-year survival [82, Figure].  
It has been estimated that all-arterial grafting is possible in 90% of patients using various 
conduits and their configurations [55], and even patients with advanced age have been 
shown to benefit from all-arterial revascularization strategies in terms of freedom from 
recurrent coronary events and improved graft patency [83].  
6. Bilateral internal mammary artery conduits 
In the 1980s, the LIMA-to-LAD graft was shown to be an independent predictor of 
improved short- and long-term results when used as a conduit for CABG compared to 
RSVG-only grafting [76]. Unequivocal advantages of the LIMA-LAD graft include 
prolonged survival relative to use of RSVG to LAD, reduced rates of recurrent angina, 
reduced postoperative MI and other ischemic events, and decreased need for coronary 
reintervention [76, 84]. The superiority of the LIMA in comparison to other CABG conduits  
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Fig. 1. Effects of completeness of revascularization on 12-year old Kaplan-Meier survival in 
triple-vessel disease (3-Ves Dis) patients. (Left) All-arterial patients. (Right) Internal thoracic 
artery/saphenous vein (ITA/Vein) patients. Incomplete - completeness of revascularization 
index (CRI) less than 1, or 2 grafts; complete CRI equal to 1, or 3 grafts; complete plus - CRI 
greater than 1, or 4 or more grafts. All p values by log-rannk (Mantel-Cox) test. (CABG - 
coronary artery bypass graft surgery.) 
may be related to its unique freedom from arteriosclerosis and due to the rich run-off bed 
provided by the LAD coronary and its branches [85]. Since there is no basis for suggesting 
or concluding that the biological and mechanical properties of the right IMA are different 
from the LIMA, successes with the LIMA have prompted investigation of the potential 
benefits of bilateral IMA (BIMA) grafting. 
The original description of BIMA for CABG is credited to Kay in 1969 [86]. Since then, 
multiple centers including our own have investigated the impact of BIMA grafting on long-
term results of CABG. Advantages of BIMA have been somewhat difficult to prove 
definitively without randomized controlled trials in this area, which have not been 
conducted secondary to cost concerns and administrative requirements associated with 
studies inherently requiring significant longitudinal follow-up [87]. Instead, investigation 
and documentation of BIMA benefits have relied on evaluating institutionally maintained 
observational databases to show differences between the “treatment group” and the 
“control group” by way of propensity matching [87]. Analysis of these data show improved 
long-term results for patients receiving BIMA grafting as compared with single IMA 
grafting. However, survival curves do not separate until several years postoperatively, 
which has been a consistent finding [15, 88, 89; Figure]. The demonstrated clinical 
advantages of BIMA grafting strategies include prolonged survival and reduced need for 
coronary reintervention on the basis of recurrent myocardial ischemia, including freedom 
from the need for coronary reintervention [15, 88, 90] which hold true for women as well as 
for men, where it has been demonstrated that use of BIMA had 3-fold improved cardiac-
related survival compared with patients who did not receive an IMA graft [91].  
Reported rates of BIMA use in CABG range from 4.0% to nearly 50% depending upon 
several factors including the contributing authors’ practice preferences and the particular 
patient cohort treated [19-22, 92]. However, it has been estimated that up to 80% would be 
candidates for BIMA grafting [93]. Subjective and potential obstacles to BIMA use include 
increased surgical times, increased technical challenges, especially related to the positioning  
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Fig. 2. 
of the non-LIMA-to-LAD graft, and increased rates of sternal wound complications relative 
to patients with one or less IMAs harvested [94]. After 10 years of experience with BIMA 
CABG, Gansera et al noted increased OR and aortic cross clamp times among BIMA patients 
compared with single IMA CABG patients. In addition, patients receiving BIMA grafting 
had higher rates of bleeding requiring postoperative mediastinal reexploration (2.9% vs. 
0.6%) along with increased rates of wound complications [95]. However, they also noted 
that nearly one full additional distal graft was completed when both IMAs were used and, 
most importantly, BIMA grafting was associated with improved 30-day survival, 
particularly among diabetic patients, compared with only one IMA graft. [95]. In this same 
study, a grafting strategy not incorporating 2 IMA conduits was an independent predictor of 
perioperative mortality, directly disputing biases that BIMA grafting is associated with 
increased perioperative complications [95]. Similarly, Kurlansky et al reviewed their 
collective experience with more than 4,500 consecutive CABG procedures (2,369 single IMA; 
2,215 BIMA) and demonstrated that hospital mortality was significantly reduced among 
patients undergoing BIMA grafting compared with controls [92].  
Nevertheless, selection of patients for BIMA grafting should be performed cautiously, 
particularly when performing surgery through a standard median sternotomy incision. This 
is primarily related to the well-demonstrated risk for sternal wound infection after BIMA 
grafting in patients with diabetes, obesity, and other comorbidities [96-100]. However, 
BIMA grafting can be performed safely without significant increased risk for sternal wound 
infection as has been frequently demonstrated [24, 98, 100, 101]. For example, Jones et al 
reviewed their experience with 500 consecutive patients undergoing BIMA CABG over an 
11-year period, excluding only those with proximal coronary stenoses <70% and emergency 
cases with HD instability. Nevertheless, the reported rates of perioperative complications 
were low: operative mortality was 1.8%; deep sternal wound infections were 1%; and 1.8% 
had take back for bleeding. Incredibly, only 2 patients out of the 500 required reoperation 
for myocardial ischemia in the follow-up period. [24]. Interestingly, however, Jones et al 
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point out that if strict criteria for selecting patients for BIMA grafting had been used, nearly 
70% of patients in their series would have been excluded [24].  
As noted previously, RSVG conduits for CABG have not been compared directly to DES, but 
comparisons of BIMA grafting with a strategy primarily employing DES for coronary 
revascularization do exist [102, 103]. After matching for multiple comorbidities, significantly 
improved angina, reduced need for reintervention, and improved reintervention-free 
survival at one year have been observed among patients undergoing BIMA CABG relative 
to PCI [102]. In a similar study, Locker et al examined BIMA CABG versus PCI in diabetic 
patients and demonstrated more complete coronary revascularization, improved angina, 
reduced need for reintervention, and increased cardiovascular event-free survival (80% vs. 
30%, p <0.001) in patients undergoing BIMA CABG [103]. More importantly, 6-year survival 
among patients with left main CAD or 3-vessel CAD was significantly better with BIMA 
revascularization, providing rare evidence for superiority of multiple arterial grafting 
strategy relative to PCI [103]. 
One controversial and often-debated point concerning BIMA CABG relates to the native 
coronary artery planned as a target for the second (right) IMA. Initial opinion considered 
best results of BIMA CABG to occur when the RIMA was grafted to the “next most” 
important coronary bed angiographically, assuming that LIMA to LAD was nearly always 
performed [104]. Schmidt et al found that multiple left-sided grafts lead to improved 
survival relative to a cohort of patients in which the RIMA was placed to the right coronary 
artery distribution along with LIMA-LAD grafting [104]. However, it should be noted that 
graft patency was quite good in both groups (91.7 % vs. 89.6%), as was survival, and 
freedom from heart failure, angina and need for reintervention [104]. They argued that 
maximum long-term benefit from BIMA grafting is realized when the 2nd IMA is placed to 
the coronary distribution subtending the most amount of viable myocardium, which was 
most commonly the circumflex artery distribution. 
The requirement for the 2nd IMA targeted to the left coronary system has been refuted by 
other data. Analysis of Cleveland Clinic data shows that benefits of BIMA CABG are similar 
regardless of the recipient coronary artery for the 2nd IMA graft [89]. Sabik et al found that 
risk-adjusted and unadjusted outcomes did not differ between a strategy for the 2nd IMA 
going to the right coronary or the circumflex coronary artery territory, but several important 
caveats are applicable, particularly with regard to the right coronary artery if the RIMA is to 
be used as an in situ graft to this coronary distribution. For instance, the distal RCA should 
be free of disease, and the proximal RCA stenosis should be  70% in diameter to avoid 
competitive native coronary flow, which may be detrimental to IMA patency. Finally, distal 
viable myocardium should be ensured [105]. More recently, Kurlansky et al reviewed their 
experience in over 2,200 consecutive patients who underwent BIMA grafting. In 2/3 of 
patients, the 2nd IMA was placed to the left coronary system, while in 1/3 of patients, the 2nd 
IMA was placed to the right coronary system. Incredibly, 98% of patients had complete 
coronary revascularization performed with in-situ arterial configurations, that is, avoiding 
free IMA utilization. At a mean follow-up of nearly 13 years, long-term survival was no 
different between groups [106, Figure]. 
Gansera et al recently described their strategy for with BIMA versus single IMA in which 
the RIMA was usually directed anteriorly and to the left as pedicled conduit for the LAD, 
while the LIMA was typically directed for revascularization of the lateral wall (circumflex 
artery distribution) [95]. Importantly, RIMA crossover grafts to the LAD coronary system 
appear to have patency rates that are not different from LIMA-LAD configurations [107]. In  
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Fig. 3. Actuarial survival of optimally matched patients who underwent coronary artery 
bypass grafting to the left coronary system (LCS [boxes]) and the right coronary system 
(RCS [triangles]). Number of patients at risk is in parentheses; results are mean = standard 
error of the mean. 
fact, Chow et al reported that RIMA patency was similar to LIMA patency regardless of the 
coronary distribution to which the artery was grafted [108]. However, a “crossover” 
configuration for the RIMA places the RIMA-LAD graft at significant risk for injury during 
subsequent redo sternotomy (as potentially required for aortic valve replacement or other 
procedures). Consequently, when performing this procedure, we often apply a protective 
barrier to the mediastinum prior to sternal closure (Repel-CV, SyntheMed, Inc., Iselin, NJ, 
USA) and often reapproximate the thymic remnant to protect the RIMA-LAD graft [108].  
Therefore, the specific BIMA configuration doesn’t seem to affect MACE, graft patency, or 
morbidity/mortality outcomes [110]. Glineur et al evaluated BIMA grafting with both IMA 
grafts targeted to the left coronary system in either an in-situ or Y-graft configuration, noting 
equivalent patencies and other mid-term results. In addition, the T-graft configuration has 
been shown to be safe and effective in grafting multiple distal coronary targets [111].  
Most results with BIMA grafting are improved by harvesting the conduit as a “skeletonized” 
graft rather than as a pedicled graft, in which the accompanying mammary veins and 
surrounding chest wall muscle and fascia were mobilized along with the artery. Skeletonized 
IMA harvesting preserves sternal perfusion relative to pedicled IMA harvesting [112, 113]. As 
a result, skeletonized IMA harvesting is associated with reduced sternal wound complications 
and longer IMA graft length, allowing more distal coronary targets to be bypassed [Figure, 92, 
98, 100]. Skeletonized IMAs also have increased blood flow through the conduit [114], possible 
as the result of decreased spasm, since skeletonized IMA is typically accomplished without the 
need for electrocautery on the chest wall [100, 106, 115]. 
7. Radial artery 
Professor Alain Carpentier is credited with introducing the radial artery (RA) as an alternative 
conduit for CABG [116], but initial results with the RA were unfavorable, leading Carpentier 
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and others to abandon its use. Subsequently, several RA grafts were empirically observed to 
be patent at follow-up coronary angiography, leading to the concept’s reintroduction in the 
late 1980s [117]. Since then, the RA has since been widely used and aggressively investigated 
as a conduit option for CABG due to ease of use, availability in at least 90% of patients, good 
length allowing reach to any distal target for anastomosis, and it is amenable to concurrent 
harvesting methods (the IMA, SVG, and RA can be harvested simultaneously) [118]. 
Depending upon the details of RA grafting, including the target coronary bed and the 
proximal degree of coronary artery stenosis, long-term RA graft patency approaches 90% and 
can approximate that of pedicled IMA graft patencies [55, 119, 120]. 
Since most coronary grafting strategies employing RA grafts do so to evaluate alternatives 
to SVG conduits, numerous trials comparing RA with SVG for patency and long-term 
outcomes have been conducted recently [14, 78, 121-123]. In general, these data demonstrate 
equivalent or improved patency for the RA compared with SVG. One recent randomized 
controlled trial in the US Veterans Affairs system evaluated RA and SVG as coronary bypass 
grafts to the “best remaining recipient vessel,” with the primary end point of one-year 
angiographic patency [123]. These data demonstrated equivalent graft patencies for RA 
compared with SVG, but one-year patency for both groups approached 90% [123]. This is in 
line with many previous reports on early RA patency, and far exceeds other recent 
estimations of early graft SVG patency for [8-10]. In contrast, the Radial Artery Versus 
Saphenous Vein Patency (RSVP) trial compared 5-year graft patency for RA versus SVG 
when placed to circumflex coronary artery branches that were at least 70% stenotic [121]. 
These data demonstrated a significantly improved patency for RA grafts (98.3%) relative to 
SVG grafts (86.4%) [122].  
Perhaps the most recognized comparison of RA and SVG is provided by the Radial Artery 
Patency Study (RAPS), which randomized 561 patients at 13 centers (Canada, New Zealand) 
to receive a RA graft to the right coronary system or the circumflex coronary system [78]. 
Saphenous vein grafts were placed to the coronary system not receiving the RA graft, and 
all patients underwent LIMA-LAD grafting. One-year angiographic follow-up was 
performed in 440 patients and demonstrated significantly improved patency for RA grafts 
compared with SVG (91.8% vs. 86.4%, p = 0.009). However, angiographic “string sign” was 
significantly increased in RA grafts compared with SVG (7% vs. 0.9%, p = 0.001) [78]. It is 
unclear as to the long-term significance of this finding; as Carpentier originally noted, others 
have since reported that patency of the RA graft with a “string sign” may actually improve 
as the native disease worsens [124]. When patient characteristics and target vessel 
characteristics were considered in the interpretation of the RAPS data, RA grafts were 
protective of graft patency by multivariable analysis, while smaller distal targets, less 
proximal coronary artery stenosis, and diabetes were associated with reduced patency rates 
for SVG or RA grafts [125]. Graft occlusion was significantly more common among diabetics 
with SVG (19%) compared with RA grafts in diabetics (12%). In fact, RA grafting conferred 
even greater protection effect from graft occlusion was among diabetic patients than in the 
study cohort as a whole [125].  
Despite the positive comparisons of RA with SVG patency rates, it has been more difficult to 
ascribe improved clinical outcomes with RA versus SVG [126]. However, some data suggest 
that better long-term survival is seen in those receiving RA conduits as compared with SVG 
(Figure). Zacharias et al evaluated the influence of RA and SVG as a 2nd graft (all patients 
receiving LIMA-LAD) with regard to survival in 2 groups of 925 matched patients each [14]. 
6-year survival was improved in RA patients [14, Figure.].  
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Fig. 4.  
Similar data have been reported by Tranbaugh et al, who compared over 800 patients 
undergoing CABG utilizing LIMA, RA, and SVG with matched patients undergoing CABG 
with LIMA and SVG only [127]. They showed significantly improved survival in the RA 
group in addition to improved patency of RA as compared to SVG (81% vs. 47%) in 
symptomatic patients who subsequently underwent diagnostic angiography after CABG 
(mean time to repeat catheterization 4.3 years) [127]. Importantly, RA use emerged as 
independent predictor of survivalat 14 years when the data were assessed by multivariable 
analysis [127, Figure].  
 
 
Fig. 5. Comparison of Kaplan-Meier survival for propensity-matched patents (p - 0.0011, log 
rank test), CABG - coronary artery bypass graft surgery. 
Conduct of these well-designed trials incorporating angiographic follow-up of RA grafts has 
provided a wealth of insight into features important to successful RA grafting. For example, 
as noted, early graft failures in the form of “string sign” have been noted in randomized 
trials [78], and several explanations for this are possible. For example, RA grafts appear 
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notoriously susceptible to competitive flow within the native coronary circulation, as may 
occur when native coronary stenosis is not severe ( 70%) [128, 129]. Based on this frequent 
observation, use of the RA is not recommended as a conduit for CABG unless the native 
coronary artery stenosis is high grade ( 70%). This strategy has been associated with 
improved patency and reduced “string sign” in the RAPS study [78]. Radial artery graft 
patency is also dependent upon coronary target location, as has been noted for the RIMA 
graft [89]. For instance, Maniar et al found that grafts to the right coronary artery were more 
likely to be occluded compared with those placed to the LAD or to the circumflex coronary 
artery [129], which has been corroborated by others [130].  
Certain inherent, unique characteristics of the RA may also contribute to “string sign” 
formation [131]. Limb arteries such as the RA are known to be more prone to spasm than 
somatic (IMA) or splanchnic arteries [132]. One key difference between the IMA and the RA 
is that the RA is significantly more muscular, leading to increased tendency for spasm 
requiring prolonged vasodilation [133]. Vasodilation of the harvested RA should begin 
intraoperatively by exposing the conduit to papaverine or verapamil/nitroglycerin. 
Verapamil/nitroglycerin may be more effective than papaverine in regards to degree of 
vasodilation and preservation of endothelial function, which can be a problem with 
papaverine (especially if injected intraluminally) and with the alpha-blocking agent 
phenoxybenzamine [118]. Postoperatively, most authors have recommended vasodilation 
with calcium channel blocking agents or long-acting nitrates for at least one month after 
surgery. 
It is debated as to whether the proximal RA graft anastomosis should be performed to the 
ascending aorta or as a composite graft to other conduits. In a study of over 1,500 radial 
artery grafts, Maniar et al found no difference between these two types of grafting strategies 
[129]. Collins et al, reporting the results of the Radial Artery Versus Saphenous Vein Patency 
(RSVP) trial, demonstrated superior patency of RA grafts compared with SVG, and all 
proximal anastomoses were performed to the aorta directly [122]. Jung et al recently 
demonstrated using postoperative CT angiography that RA patency was better when the 
proximal anastomosis was made to the aorta and did not use the IMA as RA inflow [134]. 
However, Desai et al found that at one year, 21% of RA grafts going directly to the aorta had 
“some degree” of angiographic stenosis, which was significantly less than SVG proximal 
anastomoses [78]. 
Testing for appropriateness of RA harvesting to gauge the likelihood of hand ischemia after 
RA harvesting is recommended. The Modified Allen’s Test (MAT) is abnormal in wide 
ranges (<1% to 27%), often attributed to observer variability [135]. When MAT was 
compared with Doppler ultrasonography of the thumb artery, MAT was noted to have a 
sensitivity of 100% and specificity of 97% for thumb ischemia [136]. Various adjuncts to the 
MAT have been proposed, including pulse oximetry, plethysmography, and Doppler 
ultrasonography of the hand [136-138]. However, none of these modalities have been 
proven to add significantly to the diagnostic accuracy of a properly performed MAT, which 
appears to accurately and safely select patients for RA harvesting.  
Harvesting of the RA has been performed traditionally by the open, “no-touch” technique 
[127]. However, more recently, the trend appears to have shifted toward endoscopic RA 
harvesting with demonstrated functional and cosmetic advantages [139] and no increase in 
vasoreactivity or damaged endothelium [140]. However, harvesting the RA as a pedicle with 
harmonic scalpel appears to be less injurious than using electrocautery for tissue dissection 
[140]. Patency rates are similar regardless of method of harvesting [142]. 
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8. Summary 
Coronary artery bypass grafting remains one of the most frequently performed major 
operations worldwide. Even in the burgeoning era of percutaneous approaches to coronary 
heart disease, the indications for CABG continue to be based on relief of angina, prevention 
of myocardial damage from ischemic complications, and prolonged expected survival in 
select patients. In order to provide the best results for CABG patients, the surgeon’s chief 
focus should be on improved long-term outcomes. Based on the information available, the 
best long-term outcomes of CABG are achieved when incorporating a strategy of grafting 
with arterial conduits.  
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